
BioPorto Investor Relations Material
Latest events

Q1 2025
BioPorto

Q1 2025
8 May, 2025

Q4 2024
20 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioPorto
Access all reports
BioPorto A/S is a global biotech company that specializes in the development and manufacturing of in-vitro diagnostic tests and antibodies for both research and clinical applications. The company's diagnostics products are primarily based on a patented proprietary technology platform called MoAb®. The Company's products are used in research, including preclinical studies and clinical trials, as well as in diagnosis procedures to detect infectious diseases, cancer, autoimmune disorders and other diseases. BioPorto A/S is based in Hellerup, Denmark.
Key slides for BioPorto
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
BIOPOR
Country
🇩🇰 Denmark